Holen Sie sich die Stockscreener-App
34.03
0.98%
0.32
Schlusskurs vom Vortag:
$33.71
Offen:
$34.29
24-Stunden-Volumen:
118.22K
Relative Volume:
3.65
Marktkapitalisierung:
$135.72M
Einnahmen:
$17,000
Nettoeinkommen (Verlust:
$-31.08M
KGV:
-10.17
EPS:
-3.3463
Netto-Cashflow:
$-24.86M
1W Leistung:
-3.87%
1M Leistung:
+0.50%
6M Leistung:
+72.27%
1J Leistung:
+133.79%
1-Tages-Spanne:
$31.21
$37.15
1-Wochen-Bereich:
$31.21
$38.44
52-Wochen-Spanne:
$14.00
$44.00
Vtv Therapeutics Inc Stock (VTVT) Company Profile
Firmenname
Vtv Therapeutics Inc
Sektor
Branche
Telefon
336-841-0300
Adresse
3980 PREMIER DR, HIGH POINT, NC
Compare VTVT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
34.47 | 132.75M | 17,000 | -31.08M | -24.86M | -3.3463 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.57 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.28 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.71 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.76 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.67 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-23 | Eingeleitet | Roth Capital | Buy |
| 2026-01-05 | Eingeleitet | TD Cowen | Buy |
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2019-05-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-04-10 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-08 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-08 | Eingeleitet | Northland Capital | Outperform |
| 2016-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-09-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-08-24 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-08-24 | Eingeleitet | Stifel | Buy |
Alle ansehen
Vtv Therapeutics Inc Aktie (VTVT) Neueste Nachrichten
HC Wainwright Forecasts Higher Earnings for vTv Therapeutics - MarketBeat
Evercore ISI initiates vTv Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
This Jabil Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Evercore ISI Initiates vTv Therapeutics at Outperform With $44 Price Target - marketscreener.com
Evercore ISI Initiates Coverage on VTVT with Outperform Rating | VTVT Stock News - GuruFocus
Research Analysts Set Expectations for VTVT Q1 Earnings - MarketBeat
vTv Therapeutics (NASDAQ:VTVT) Share Price Crosses Below 50-Day Moving AverageShould You Sell? - MarketBeat
vTv Therapeutics (VTVT) Projected to Post Earnings on Thursday - Defense World
Avoiding Lag: Real-Time Signals in (VTVT) Movement - Stock Traders Daily
BTIG Maintains Buy on vTv Therapeutics Inc (VTVT) March 11, 2026 - Meyka
BTIG reiterates Buy on vTv Therapeutics stock, $49 target maintained By Investing.com - Investing.com Canada
VTVT: BTIG Reiterates Buy Rating with Unchanged Price Target | V - GuruFocus
BTIG reiterates Buy on vTv Therapeutics stock, $49 target maintained - Investing.com
vTv Therapeutics 2025 – Pipeline, Clinical Trials, and Patent Portfolio Overview - Minichart
vTv Therapeutics price target raised to $55 from $35 at Alliance Global - TipRanks
VTv Therapeutics: Q4 Earnings Snapshot - theheraldreview.com
vTv Therapeutics Highlights Cadisegliatin Phase 3 and Cash Runway - TipRanks
vTv Therapeutics 2025 10-K: $0.0M Revenue, $(26.97)M Net Loss - TradingView
VTv Therapeutics: Fourth Quarter Earnings Overview - Bitget
VTV Therapeutics (VTVT) Quarterly & Annual Financial Results 2026News and StatisticsIndexBox - IndexBox - Market Intelligence Platform
VTVT Stock Bolstered by Strong Financials and Strategic Advances - GuruFocus
vTv Therapeutics reports Q4 EPS (58c), consensus ($1.09) - TipRanks
vTv Therapeutics (VTVT) boosts cash, advances Phase 3 CATT1 trial - Stock Titan
vTv Therapeutics Q4 net loss widens on higher expenses - TradingView
vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Weekly Voice
Vtv Therapeutics: Capital Efficiency and Clinical Catalysts Under Scrutiny - AD HOC NEWS
Aug Shorts: Will vTv Therapeutics Inc outperform the market in YEAREarnings Risk Report & Verified Technical Trade Signals - baoquankhu1.vn
How vTv Therapeutics Inc. (5VT0) stock correlates with oil marketsJuly 2025 WrapUp & Fast Entry High Yield Tips - Naître et grandir
vTv Therapeutics (VTVT) Secures Global Partnership for PDE4 Inhibitor HPP737 - Yahoo Finance
12 Most Promising Micro-Cap Stocks According to Analysts - Insider Monkey
Discipline and Rules-Based Execution in VTVT Response - Stock Traders Daily
VTv Therapeutics: Cadisegliatin's Phase 3 CATT1 Readout Is The Next Catalyst - Seeking Alpha
VTVT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Up 61.2% in February - MarketBeat
VTVT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
VTVT PE Ratio & Valuation, Is VTVT Overvalued - Intellectia AI
vTv Therapeutics Highlights Cadisegliatin Progress and Financial Strength - TipRanks
vTv Therapeutics posts updated investor presentation highlighting Phase 3 cadisegliatin readout and $118.5M liquidity - TradingView
vTv Therapeutics (VTVT) spotlights cadisegliatin Phase 3 and cash runway - Stock Titan
VTVT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Quarterly Earnings: Can US Physical Therapy Inc deliver consistent EPS growth2025 Earnings Impact & Breakout Confirmation Trade Signals - baoquankhu1.vn
What are analysts’ price targets for vTv Therapeutics Inc.2025 Retail Activity & Short-Term Trading Opportunity Alerts - mfd.ru
Can vTv Therapeutics Inc. sustain earnings growthProfit Target & Long-Term Safe Investment Plans - mfd.ru
vTv Therapeutics (NASDAQ:VTVT) Shares Pass Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Stock Analysis: What are analysts price targets for vTv Therapeutics IncMarket Activity Report & Weekly Watchlist of Top Performers - baoquankhu1.vn
vTv Therapeutics (VTVT) CFO granted 44,969 stock options at $36.92 - Stock Titan
Behavioral Patterns of VTVT and Institutional Flows - Stock Traders Daily
What’s next for vTv Therapeutics Inc. stockMarket Trend Report & AI Powered Buy/Sell Recommendations - mfd.ru
Why vTv Therapeutics Inc. stock could see breakout soonJuly 2025 Fed Impact & High Accuracy Swing Trade Signals - mfd.ru
vTv Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Finanzdaten der Vtv Therapeutics Inc-Aktie (VTVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):